LipoMedix

growth-positive

LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, has announced positive Phase 1 data for its drug, Promitil, in patients with metastatic colorectal cancer. The study, published in the research journal Investigational New Drugs, demonstrated positive results on the pharmacokinetics and clinical observations of the drug. Promitil was well-tolerated with a good safety profile and resulted in a substantial rate of disease stabilization. The treatment resulted in a median survival of 14.4 months, significantly longer than of progressive disease patients. The company plans to further develop Promitil as a novel and smart tool to overcome the problems associated with mitomycin-c toxicity.

growth-positive

LipoMedix Pharmaceuticals has announced the addition of Miranda J. Toledano and Praveen Tyle, Ph.D., to its board of directors. The company has also formed an executive committee of the board to enhance governance and support its development. Toledano and Tyle will join Sanjeev Luther, chairman of the board, on the executive committee. Toledano has over 20 years of executive experience in the biopharmaceutical sector, while Tyle is currently the executive vice president of research and development at Lexicon Pharmaceuticals. Alberto Gabizon, M.D., Ph.D., co-founder of LipoMedix, will now serve as president of the company. LipoMedix is focused on the development of an innovative cancer therapy based on liposome delivery.

growth-positive

LipoMedix, a clinical-stage pharmaceutical company, announced that new clinical data of Promitil® in patients with metastatic colorectal cancer will be presented at the AACR annual meeting. The study shows disease stabilization and extended survival in a significant fraction of patients. Promitil® is a liposomal drug delivery platform that enables efficient and selective tumor delivery of MLP, a chemical entity known as mitomycin-c lipidic prodrug. The presentation will take place on April 1, 2019.

growth-positive

LipoMedix, a clinical-stage pharmaceutical company, has announced the initiation of a Phase 1b multicenter trial to evaluate the safety and efficacy of its lead compound Promitil® in combination with external beam radiotherapy (EBR) for advanced cancer patients. The trial, approved by Israels Ministry of Health, is expected to be completed by Q1 2020. Promitil® is a liposomal prodrug of mitomycin C, which has shown promising clinical activity as a treatment for metastatic colon cancer and has the potential to become a curative tool in chemo-radiotherapy. LipoMedix plans to develop Promitil® for other difficult-to-treat cancers as well. Investors in LipoMedix include Rafael Holdings. The company aims to deliver efficient and selective tumor delivery of Promitil® through its pegylated liposome delivery platform.